Golden eagle optimized CONV-LSTM and non-negativity-constrained autoencoder to support spatial and temporal features in cancer drug response prediction.

Advanced machine learning (ML) and deep learning (DL) methods have recently been utilized in Drug Response Prediction (DRP), and these models use the details from genomic profiles, such as extensive drug screening data and cell line data, to predict the response of drugs. Comparatively, the DL-based prediction approaches provided better learning of such features. However, prior knowledge, like pathway data, is sometimes discarded as irrelevant since the drug response datasets are multidimensional and noisy. Optimized feature learning and extraction processes are suggested to handle this problem. First, the noise and class imbalance problems must be tackled to avoid low identification accuracy, long prediction times, and poor applicability. This article aims to apply the Non-Negativity-Constrained Auto Encoder (NNCAE) network to tackle these issues, enhance the adaptive search for the optimal size of sliding windows, and ensure that deep network architectures are adept at learning the vital hidden features. NNCAE methodology is used after performing the standard pre-processing procedures to handle the noise and class imbalance problem. This class balanced and noise-removed input data features are learned to train the proposed hybrid classifier. The classification model, Golden Eagle Optimization-based Convolutional Long Short-Term Memory neural networks (GEO-Conv-LSTM), is assembled by integrating Convolutional Neural Network CNN and LSTM models, with parameter tuning performed by the GEO algorithm. Evaluations are conducted on two large datasets from the Genomics of Drug Sensitivity in Cancer (GDSC) repository, and the proposed NNCAE-GEO-Conv-LSTM-based approach has achieved 96.99% and 97.79% accuracies, respectively, with reduced processing time and error rate for the DRP problem.